ReviewClinical microbiology reviews2014
Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future.
Review in Clinical microbiology reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05581160 (Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI), which is not on this map. Cited by 608 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)
Who cites it
608 citing papers in PubMed, 8 syntheses or guidelines pooled it, 1,163 citations in OpenAlex.
- Temporal and geographic trends in extended-spectrum cephalosporins resistance among Neisseria gonorrhoeae isolates worldwide: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.The Journal of infectious diseases · 2025Pooled it
- A systematic review of Neisseria gonorrhoeae drug resistance development in South Africa.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Pooled it
- 45 years of tetracycline post exposure prophylaxis for STIs and the risk of tetracycline resistance: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- The frequency of mutations in theFrontiers in microbiology · 2024Pooled it
- Global trends of antimicrobial resistance rates inFrontiers in pharmacology · 2024Pooled it
- Pooled it
- Economic evaluation of antimicrobial resistance in curable sexually transmitted infections; a systematic review and a case study.PloS one · 2023Pooled it
- Fluoroquinolone resistance-conferringAntimicrobial agents and chemotherapy · 2026Article
- Heterogeneity of azithromycin resistance markers inNew microbes and new infections · 2026Review
- Measuring the health benefits and costs of antimicrobial-resistant gonorrhea surveillance in the United States: an agent-based model and cost-effectiveness analysis.Lancet regional health. Americas · 2026Article
- Article
- Development and Laboratory Evaluation of aInternational journal of molecular sciences · 2026Article
- An antibody-drug conjugate active against antibiotic-resistantProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Mechanisms of Resistance, Insights From Case Reports, and Future Prospects in Mycobacteriophage Therapy.Journal of the Royal Society of New Zealand · 2026Review
- Put your money where your mouth is: surveillance of antibiotic resistance within the commensalMicrobiology spectrum · 2026Article
- Trends and risk factors of antimicrobial resistance of Neisseria gonorrhoeae in Catalonia, Spain, 2022-2023.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Comparing Phenotypic Susceptibility Profiles of Neisseria gonorrhoeae for Tetracycline and Doxycycline.Sexually transmitted diseases · 2026Article
- The Path of Estimated Resistance: Updates of the Estimated Number and Cost of Antimicrobial-Resistant Gonococcal Infections in Men and Women Aged 15 to 39 Years in the United States: 2018-2023.Sexually transmitted diseases · 2026Article
- Rapid Cas13a-basedmSphere · 2026Article
548 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Neisseria gonorrhoeae is evolving into a superbug with resistance to previously and currently recommended antimicrobials for treatment of gonorrhea, which is a major public health concern globally. Given the global nature of gonorrhea, the high rate of usage of antimicrobials, suboptimal control and monitoring of antimicrobial resistance (AMR) and treatment failures, slow update of treatment guidelines in most geographical settings, and the extraordinary capacity of the gonococci to develop and retain AMR, it is likely that the global problem of gonococcal AMR will worsen in the foreseeable future and that the severe complications of gonorrhea will emerge as a silent epidemic. By understanding the evolution, emergence, and spread of AMR in N. gonorrhoeae, including its molecular and phenotypic mechanisms, resistance to antimicrobials used clinically can be anticipated, future methods for genetic testing for AMR might permit region-specific and tailor-made antimicrobial therapy, and the design of novel antimicrobials to circumvent the resistance problems can be undertaken more rationally. This review focuses on the history and evolution of gonorrhea treatment regimens and emerging resistance to them, on genetic and phenotypic determinants of gonococcal resistance to previously and currently recommended antimicrobials, including biological costs or benefits; and on crucial actions and future advances necessary to detect and treat resistant gonococcal strains and, ultimately, retain gonorrhea as a treatable infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.